Cargando…
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
The frontline treatment options for patients with metastatic renal cell carcinoma (mRCC) are evolving rapidly since the approval of combination immunotherapies by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA). In particular, in combination with vascular endoth...
Autores principales: | Mennitto, Alessia, Huber, Veronica, Ratta, Raffaele, Sepe, Pierangela, de Braud, Filippo, Procopio, Giuseppe, Guadalupi, Valentina, Claps, Mélanie, Stellato, Marco, Daveri, Elena, Rivoltini, Licia, Verzoni, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231111/ https://www.ncbi.nlm.nih.gov/pubmed/32231117 http://dx.doi.org/10.3390/jcm9040930 |
Ejemplares similares
-
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020) -
Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience
por: Sepe, Pierangela, et al.
Publicado: (2019) -
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
por: Bottiglieri, Achille, et al.
Publicado: (2022) -
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019) -
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)